New hope for kidney cancer: triple therapy trial launches
NCT ID NCT05663710
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This study tests a combination of three drugs (177Lu girentuximab, cabozantinib, and nivolumab) in people with advanced clear cell kidney cancer who have not had prior treatment. The goal is to see if the combination can control the cancer and to check for side effects. About 100 adults with measurable tumors and good overall health are being recruited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A lifeline for cancer caregivers: can simple phone support reduce their stress?
- A digital lifeline: could Real-Time symptom tracking transform care for kids with advanced cancer?
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can a 30-hour e-learning course equip family doctors to deliver better palliative care?
- Can a new nucleotide analogue boost cancer treatment?
- Can a tracer that hunts unstable iron light up hidden tumors?